Point of Care Diagnostics Market is expected to reach USD 53.98 billion by the year 2028, at a CAGR of 8.6%.

North American region is anticipated to have the highest share of the point of care diagnostic market in the forecast period due to the growing awareness about the diagnosis of diseases.

Spread the love

Global Point of Care Diagnostics Market was valued at USD 30.30 billion in 2021 and is expected to reach USD 53.98 billion by the year 2028, at a CAGR of 8.6%.

Point-of-care testing (POCT) is critical for detecting analytes close to the patient, allowing for better disease diagnosis, monitoring, and management. It allows for quick medical decisions because diseases can be diagnosed at an early stage, resulting in better health outcomes for patients by allowing for the early start of treatment.

Point of Care Diagnostics market research includes a thorough competitor study analysis and SWOT analysis. According to the market study, report covers key players market share and global impression through collaborations, mergers and acquisitions, joint ventures, partnerships, agreements and product launches. The research examines macroeconomic and microeconomic variables that may affect market demand and growth. The research reports covers COVID-19 impact on  current market position as well as regional analysis for future growth. The market size, share, production, revenue, production, gross margin, pricing, and market-influencing factors are all covered in research report. The market research report is in-depth examined for the relevant time frame.

Read Complete Research @

 Point Of Care Diagnostics MarketLeading Key Players:

  • F. Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Thermo Fisher Scientific Inc. (Massachusetts, U.S.)
  • Abbott Laboratories (Illinois, U.S.)
  • Quest Diagnostics Incorporated (New Jersey, U.S.)
  • BD (Franklin Lakes, U.S.)
  • BioMerieux SA (Marcy l’Etoile, France)
  • Cardinal Health, Inc. (Ohio, U.S.)
  • Mesa Biotech (California, U.S.)
  • Cepheid (California, U.S.)
  • Trinity Biotech (Bray, Ireland)
  • Quidel Corporation (San Diego, U.S.)
  • Bio-Rad Laboratories Inc. (California, U.S.) and Other Major Players.

 Download Sample Copy @

Market Dynamics and Factors:


  • Increasing Prevalence Of Chronic Diseases


  • Adoption Of Point-Of-Care Diagnostics Is Inadequate


  • Technological Advancement In POC Diagnostic

 Market Segment:

By Application 

  • Infectious Disease Testing Products
  • Glucose Monitoring Products
  • Pregnancy
  • Fertility Testing Products
  • Cardiometabolic Monitoring Products
  • Others

By Platform       

  • Molecular Diagnostic
  • Immunoassays
  • Lateral Flow Assays
  • Others

By End-User      

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Home Care
  • Others

Customized Research @

Market Segment by Region:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Industry Development In The Point Of Care Diagnostics Market

In January 2022, Roche launched its Cobas Pulse System in countries that accept the CE Mark. This is the latest generation of connected point-of-care solutions from Roche Diagnostics for professional blood glucose management.

In February 2021, Mesa Biotech, Inc. a privately held point-of-care molecular diagnostic company, has been acquired by Thermo Fisher Scientific Inc. Mesa Biotech created the Accula System, a point-of-care PCR-based infectious disease testing platform.

Spread the love

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button